The Motley FoolT3·14mo ago
DARE Dare Bioscience, Inc. Common Stock
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
DARE
—
—
Key stats
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 24
- List Date
- 2014-04-10
- CIK
- 0001401914
- Next Earnings
- 2026-11-12
- EPS Forecast
- ($0.09) (2 est.)
- Headquarters
- San Diego, CA
- Homepage
- https://www.darebioscience.com
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in c…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 72.52% | -24.88% | 46.38% | -1.19% | 0.93% | -7.18% | 14.43% |
| Feb | -17.62% | -6.29% | -16.13% | 66.86% | -0.32% | -3.41% | 3.85% |
| Mar | -15.08% | -0.67% | -2.80% | -10.86% | -5.25% | 13.04% | -3.60% |
| Apr | -11.70% | -33.92% | 0.00% | -37.89% | 1.72% | 20.00% | -10.30% |
| May | -14.09% | 6.96% | 0.00% | 24.28% | 1.37% | -4.70% | 2.30% |
| Jun | 46.51% | -1.60% | -9.89% | -18.02% | -21.12% | -3.65% | -1.30% |
| Jul | -12.50% | -6.72% | -17.95% | -9.63% | 1.27% | -42.86% | -14.73% |
| Aug | 9.38% | 0.00% | -6.26% | 4.99% | -16.53% | -40.55% | -8.16% |
| Sep | -4.57% | -9.91% | -32.05% | -10.00% | 3.45% | 10.79% | -7.05% |
| Oct | -11.52% | -6.73% | -8.74% | 31.78% | -8.84% | -24.35%* | -4.73% |
| Nov | 20.00% | -9.69% | -14.63% | -17.67% | -4.17% | -- | -5.23% |
| Dec | 17.65% | -12.63% | -13.20% | -5.45% | 15.57% | -- | 0.39% |
| Total | 53.04% | -69.92% | -62.00% | -18.53% | -31.55% | -68.21% | -32.86% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $0.75
SMA 50: $0.76
SMA 200: $1.61
Current: $0.64
EMA 12: $0.70
EMA 26: $0.75
MACD: -0.0473 | Signal: -0.0080
BEARISH
ADX (14): 35.55
TREND
+DI: 8.58
−DI: 25.01
Momentum Oscillators
RSI (14): 28.42
OVERSOLD
Stoch %K: 9.45
Stoch %D: 9.30
Williams %R: -90.33
Volume & Volatility
BB Upper: $0.89
BB Lower: $0.62
NEUTRAL
OBV: 68,091,671
Vol SMA 20: 158,416
Vol ROC: -38.41%
ATR: $0.05
True Range: $0.03
HV 20: 48.9%
HV 30: 57.9%
HV 60: 101.1%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report: Daré Bioscience (DARE)
Executive Summary
Overall Assessment: BEARISH (Confidence Level: 7/10)
Key Drivers:
- Bearish MACD signal, oversold RSI, and negative price momentum
- High volatility and beta above market average
- Recent news sentiment is generally positive, but fails to drive significant price movements
Primary Risks:
- Technical breakdown below $0.96 support level
- Increased selling pressure from institutional investors
- Regulatory issues or clinical trial setbacks that negatively impact earnings
Recent News Sentiment Impact: Neutral (average of recent headlines)
Technical Analysis
Trend Direction:
- Short-term: Bearish
- Medium-term: Bearish
- Long-term: Neutral
Support/Resistance Levels: $0.83, $0.96, $1.26, and $1.71 represent key price levels from moving averages and technical patterns.
Momentum Signals:
- RSI: Oversold (24.02), indicating potential buy signal
- MACD: Bearish signal (-0.17 / -0.01)
- Bollinger Bands: Price touching lower band, indicating oversold condition
Volume Analysis: Volume trends indicate institutional interest and increasing selling pressure.
News & Sentiment Analysis
Recent Headlines Summary:
- Neutral (4 headlines) and positive news (2 headlines) with no significant price movements
Sentiment Assessment: Positive (average sentiment from recent headlines)
Catalyst Identification:
- No imminent catalysts, but upcoming earnings announcement could drive price movement
Market Narrative: News sentiment aligns with bearish technical signals, indicating potential selling pressure.
Risk & Volatility Assessment
Risk Metrics:
- Beta: 1.04 (above market average)
- Stock Volatility: 1.03 (above average)
Options Market Signals:
- No options data available
Downside Protection: Support levels at $0.96 and $0.83 should be monitored for potential buying pressure.
Market Context & Positioning
Sector Performance:
- Daré Bioscience's sector (Healthcare) is performing above average, but the stock price remains weak.
Institutional Activity:
- Increasing selling pressure from institutional investors
Correlation Analysis: Daré Bioscience moves with market amplification, indicating increased volatility.
Relative Valuation: The stock is trading within a bearish channel, below its long-term trend.
Key Levels & Action Items
Critical Price Levels:
- $0.96 support level and $1.26 resistance level should be monitored
Breakout/Breakdown Levels:
- A breakdown below $0.83 could trigger further selling pressure
Time-Sensitive Catalysts:
- Earnings announcement in the near future (no specific date available)
Risk Management: Stop-loss levels should be set at or above $0.96, with position sizing considerations based on recent volatility.
This analysis highlights the bearish technical signals, high risk profile, and neutral news sentiment. The stock's price movement is expected to continue within a bearish channel, with potential selling pressure below $0.96 support level.
Generated
News
All DARE news →
GlobeNewswire Inc.T3·15mo ago
GlobeNewswire Inc.T3·26mo ago
Investing.comT3·27mo ago
GlobeNewswire Inc.T3·27mo ago
GlobeNewswire Inc.T3·28mo ago
GlobeNewswire Inc.T3·30mo ago
GlobeNewswire Inc.T3·31mo ago
GlobeNewswire Inc.T3·33mo ago
GlobeNewswire Inc.T3·33mo ago
Showing 1–10 of 50
Page 1 of 5
DARE Options Activity & IV Rank
Loading options activity...
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 1.1023
Alpha: -79.22%
Correlation: 0.1336
R-Squared: 1.8%
Stock Volatility: 105.2%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Above average volatility - stock moves with market amplification
Above average volatility - stock moves with market amplification
Beta & Alpha Over Time
DARE Institutional Ownership (13F)
Latest filings — 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
DARE Insider Trading (Form 4)
Latest: 2026-07-02Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-07-02 | Susan L. Kelley | Director | Award (A) | +23,696 | — | EDGAR | |
| 2026-07-02 | Robin Joan Steele | Director | Award (A) | +26,540 | — | EDGAR | |
| 2026-07-02 | Gregory W Matz | Director | Award (A) | +30,805 | — | EDGAR | |
| 2026-07-02 | William H Rastetter | Director | Award (A) | +38,862 | — | EDGAR | |
| 2026-07-02 | Jessica D. Grossman | Director | Award (A) | +26,066 | — | EDGAR | |
| 2026-06-11 | Jessica D. Grossman | Director | Grant (A) | +10,000 opt | — | EDGAR | |
| 2026-06-11 | William H Rastetter | Director | Grant (A) | +10,000 opt | — | EDGAR | |
| 2026-06-11 | Susan L. Kelley | Director | Grant (A) | +10,000 opt | — | EDGAR | |
| 2026-06-11 | Robin Joan Steele | Director | Grant (A) | +10,000 opt | — | EDGAR | |
| 2026-06-11 | Gregory W Matz | Director | Grant (A) | +10,000 opt | — | EDGAR | |
| 2026-02-20 | Sabrina Martucci Johnson | Chef Executive Officer | Grant (A) | +32,400 RSU | — | EDGAR | |
| 2026-02-02 | MarDee Haring-Layton | Chief Accounting Officer | Grant (A) | +49,000 opt | — | EDGAR | |
| 2026-02-02 | Sabrina Martucci Johnson | Chef Executive Officer | Grant (A) | +172,000 opt | — | EDGAR | |
| 2025-09-04 | MarDee Haring-Layton | Chief Accounting Officer | Grant (A) | +57,000 opt | — | EDGAR | |
| 2025-07-10 | Robin Joan Steele | Director | Grant (A) | +4,500 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
DARE Insider Holdings
6 insiders · @ $0.64
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Sabrina Martucci Johnson | Chef Executive Officer | 80,172 | $51.6K | $0 | 11 | 2026-02-20 |
| 2 | Robin Joan Steele | Director | 67,569 | $43.5K | $0 | 11 | 2026-07-02 |
| 3 | William H Rastetter | Director | 39,721 | $25.6K | $0 | 12 | 2026-07-02 |
| 4 | Gregory W Matz | Director | 30,847 | $19.9K | $0 | 10 | 2026-07-02 |
| 5 | Jessica D. Grossman | Director | 26,066 | $16.8K | $0 | 10 | 2026-07-02 |
| 6 | Susan L. Kelley | Director | 23,696 | $15.3K | $0 | 12 | 2026-07-02 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
DARE Board & Officers
As of SEC filings through Jul 2, 2026Directors 6
- William H Rastetter · since Apr 10, 2014
- Susan L. Kelley · since Oct 3, 2014
- Robin Joan Steele · since Jul 19, 2017
- Sabrina Martucci Johnson · since Jul 19, 2017
- Jessica D. Grossman · since Apr 9, 2018
- Gregory W Matz · since Sep 13, 2018
Officers 2
- MarDee Haring-Layton · Chief Accounting Officer · since Jan 26, 2024
- Sabrina Martucci Johnson · Chef Executive Officer · listed since Mar 2020
Changes in the last 10 years (19)
| Jan 26, 2024 | MarDee Haring-Layton became Chief Accounting Officer |
| Jan 24, 2024 | The company announced the departure of John A Fair as Chief Commercial Officer in an SEC filing |
| Jan 23, 2024 | The company announced the departure of Sophia Nnenna Ononye-Onyia from the board in an SEC filing |
| Jan 23, 2024 | The company announced the departure of Lisa Walters-Hoffert as Chief Financial Officer in an SEC filing |
| Jan 23, 2024 | The company announced the departure of Cheryl R Blanchard from the board in an SEC filing |
| Jan 26, 2023 | John A Fair listed as Chief Commercial Officer (previously Chief Strategy Officer) in SEC filings |
| Apr 16, 2021 | Sophia Nnenna Ononye-Onyia became a director |
| Mar 9, 2020 | Sabrina Martucci Johnson listed as Chef Executive Officer (previously Chief Executive Officer) in SEC filings |
| Mar 6, 2020 | John A Fair became Chief Strategy Officer |
| Nov 20, 2019 | Cheryl R Blanchard became a director |
| Sep 13, 2018 | Gregory W Matz became a director |
| Sep 10, 2018 | Sabrina Martucci Johnson no longer listed as a 10% owner in SEC filings |
| Apr 9, 2018 | Jessica D. Grossman became a director |
| Jul 25, 2017 | Sabrina Martucci Johnson first on file as a 10% owner |
| Jul 19, 2017 | Sabrina Martucci Johnson became a director |
| Jul 19, 2017 | Sabrina Martucci Johnson became Chief Executive Officer |
| Jul 19, 2017 | Roger Hawley became a director |
| Jul 19, 2017 | Robin Joan Steele became a director |
| Jul 19, 2017 | Lisa Walters-Hoffert became Chief Financial Officer |
Not reported recently (12)
- Roger Hawley · Last reported as a director in an SEC filing dated Jun 14, 2019
- Paul A Friedman · Last reported as a director in an SEC filing dated Apr 5, 2017
- Scott Eliasof · Last reported as SVP, Chief Scientific Officer in an SEC filing dated Jan 19, 2017
- Christopherd T Guiffre · Last reported as a director in an SEC filing dated Jan 9, 2017
- Gregg Beloff · Last reported as CFO in an SEC filing dated Jan 9, 2017
- Alejandra Carvajal · Last reported as VP, General Counsel in an SEC filing dated Jan 9, 2017
- Adrian Senderowicz · Last reported as SVP, Chief Medical Officer in an SEC filing dated Jan 9, 2017
- James E ONeill · Last reported as Principal Accounting Officer in an SEC filing dated Jan 9, 2017
- William McKee · Last reported as a director in an SEC filing dated Jan 5, 2017
- David Ross Parkinson · Last reported as a director in an SEC filing dated Jan 5, 2017
- Stuart A Arbuckle · Last reported as a director in an SEC filing dated Jan 5, 2017
- David R Walt · Last reported as a director in an SEC filing dated Jan 5, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
3 ETFs hold DARE
3 shown · $566.78K total exposure · 0.00% AUM-weighted avg weight
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.